These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10334561)

  • 1. Use of placebos in delayed-emesis studies.
    Navari RM
    J Clin Oncol; 1999 May; 17(5):1648-50. PubMed ID: 10334561
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.
    National Comprehensive Cancer Network (NCCN)
    J Support Oncol; 2004; 2(4):366. PubMed ID: 15357520
    [No Abstract]   [Full Text] [Related]  

  • 4. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
    de Wit R; van Alphen MM
    Ned Tijdschr Geneeskd; 2003 Apr; 147(15):690-4. PubMed ID: 12722531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurokinin antagonism and chemotherapy-induced emesis.
    Shanahan F; O'Sullivan GC
    Am J Gastroenterol; 1999 Nov; 94(11):3368-9. PubMed ID: 10566748
    [No Abstract]   [Full Text] [Related]  

  • 8. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurokinin antagonists as antiemetics].
    Heinzl S
    Med Monatsschr Pharm; 2003 Oct; 26(10):336-7. PubMed ID: 14587153
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacotherapy of emesis caused by cytostatic agents].
    Baggerman C
    Ned Tijdschr Geneeskd; 1982 May; 126(18):803-7. PubMed ID: 6283396
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of delayed emesis caused by chemotherapy.
    Harmon D; O'Brien B
    N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
    [No Abstract]   [Full Text] [Related]  

  • 16. New antiemetic agents.
    Gralla R
    Clin Adv Hematol Oncol; 2005 May; 3(5):350-2, 382. PubMed ID: 16167009
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metoclopramide and dexamethasone in prevention of postoperative nausea and vomiting after inhalational anaesthesia].
    Wallenborn J; Rudolph C; Gelbrich G; Goerlich TM; Döhnert J; Dörner J; Olthoff D
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Nov; 38(11):695-704. PubMed ID: 14600859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
    Gralla R
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
    [No Abstract]   [Full Text] [Related]  

  • 19. A factorial study of ondansetron, metoclopramide, and dexamethasone for emesis prophylaxis after adenotonsillectomy in children.
    Gunter JB; McAuliffe JJ; Beckman EC; Wittkugel EP; Spaeth JP; Varughese AM
    Paediatr Anaesth; 2006 Nov; 16(11):1153-65. PubMed ID: 17040305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.